Interleukin-2 receptor-targeted fusion toxin: Began Phase II trial of three dose levels and placebo in 60 patients. Doses will be given three times a week for f

Seragen Inc. (SRGN), Hopkinton, Mass. Product: Interleukin-2 receptor-targeted fusion toxin Indication: Moderate to severe plaque psoriasis Status: Began Phase II trial of three dose levels and placeb...